Patient P-01660
Synthetic patientNBL-101 · Day 111 · 55–64 · M · baseline S19Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
39%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S19
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Inflammatory activity+21
- Toxicity+17
- Nutritional resilience-14
- GI instability+10
- Treatment adherence-2
What helped?
No interventions yet.
LIFE OS recommendation
Dietary Support Protocol NP-02
66%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion31.1/100
worsening · +1.6 vs previous 14 d
Toxicity
Blood37.8/100
worsening · +8.7 vs previous 14 d
Sleep quality
Wearable34.8/100
improving · +5.0 vs previous 14 d
Energy level
Daily log4.5/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log5.9/10
worsening · +0.7 vs previous 14 d
Steps
Wearable9,710
worsening · -595 vs previous 14 d
Adherence
Companion94.1 %
stable · -2.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 60 from the failing basin, 28 from restoration.
Would help
- NP-02 Dietary Support Protocol79% improved among 19 similar · onset 10 d · confidence 54%
Would not help
- HY-01 Hydration Protocolonly 33% improved among 9 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates-1.2no signal · 32%
- Insoluble fibre+0.7no signal · 24%
- Histamine load-0.3no signal · 15%
- Alcohol-0.3no signal · 15%
- Dietary fat load-0.2no signal · 15%
- Spicy / capsaicin+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 42
- WearableHRV 25 ms, trending down
- Autonomic recovery ↓45
- WearableResting HR 73 bpm
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 4.2 · butyrate capacity 51/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 6.4 h
- Steps
- 9,041
- Resting HR
- 74 bpm
Daily log: GI score 31, nutritional resilience 51, adherence 94.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 50% | S19 | AD-05 | improved | 61 |
| P-01541 | 28% | S09 | AD-05 | no change | 43 |
| P-01377 | 27% | S11 | AD-05 | no change | 42 |
| P-01679 | 27% | S12 | AD-05 | no change | 39 |
| P-01483 | 26% | S14 | AD-05 | no change | 35 |
| P-01689 | 29% | S13 | BR-03 | no change | 50 |
| P-01350 | 28% | S19 | BR-03 | no change | 34 |
| P-01329 | 26% | S08 | BR-03 | improved | 79 |
| P-01430 | 42% | S05 | CR-01 | improved | 54 |
| P-01442 | 32% | S13 | CR-01 | improved | 61 |
| P-01371 | 31% | S06 | CR-01 | improved | 63 |
| P-01696 | 30% | S20 | CR-01 | improved | 59 |